Laura Fabbri
Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis
Fabbri, Laura; Moss, Samuel; Khan, Fasihul A.; Chi, Wenjie; Xia, Jun; Robinson, Karen; Smyth, Alan Robert; Jenkins, Gisli; Stewart, Iain
Authors
Samuel Moss
Fasihul A. Khan
Wenjie Chi
Jun Xia
Karen Robinson
Alan Robert Smyth
Gisli Jenkins
Iain Stewart
Abstract
Introduction Persisting respiratory symptoms in COVID-19 survivors may be related to development of pulmonary fibrosis. We assessed the proportion of chest CT scans and pulmonary function tests consistent with parenchymal lung disease in the follow-up of people hospitalised with COVID-19 and viral pneumonitis.
Methods Systematic review and random effects meta-analysis of proportions using studies of adults hospitalised with SARS-CoV-2, SARS-CoV, MERS-CoV or influenza pneumonia and followed up within 12 months. Searches performed in MEDLINE and Embase. Primary outcomes were proportion of radiological sequelae on CT scans; restrictive impairment; impaired gas transfer. Heterogeneity was explored in meta-regression.
Results Ninety-five studies (98.9% observational) were included in qualitative synthesis, 70 were suitable for meta-analysis including 60 SARS-CoV-2 studies with a median follow-up of 3 months. In SARS-CoV-2, the overall estimated proportion of inflammatory sequelae was 50% during follow-up (0.50; 95% CI 0.41 to 0.58; I2=95%), fibrotic sequelae were estimated in 29% (0.29; 95% CI 0.22 to 0.37; I2=94.1%). Follow-up time was significantly associated with estimates of inflammatory sequelae (−0.036; 95% CI −0.068 to –0.004; p=0.029), associations with fibrotic sequelae did not reach significance (−0.021; 95% CI −0.051 to 0.009; p=0.176). Impaired gas transfer was estimated at 38% of lung function tests (0.38 95% CI 0.32 to 0.44; I2=92.1%), which was greater than restrictive impairment (0.17; 95% CI 0.13 to 0.23; I2=92.5%), neither were associated with follow-up time (p=0.207; p=0.864).
Discussion Sequelae consistent with parenchymal lung disease were observed following COVID-19 and other viral pneumonitis. Estimates should be interpreted with caution due to high heterogeneity, differences in study casemix and initial severity.
Citation
Fabbri, L., Moss, S., Khan, F. A., Chi, W., Xia, J., Robinson, K., …Stewart, I. (2023). Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax, 78(2), 191-201. https://doi.org/10.1136/thoraxjnl-2021-218275
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 3, 2022 |
Online Publication Date | Mar 25, 2022 |
Publication Date | 2023-02 |
Deposit Date | Mar 27, 2022 |
Publicly Available Date | Apr 11, 2022 |
Journal | Thorax |
Print ISSN | 0040-6376 |
Electronic ISSN | 1468-3296 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 78 |
Issue | 2 |
Pages | 191-201 |
DOI | https://doi.org/10.1136/thoraxjnl-2021-218275 |
Keywords | Pulmonary and Respiratory Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/7655441 |
Publisher URL | https://thorax.bmj.com/content/78/2/191 |
Files
Thoraxjnl-2021-218275.R1 Proof Hi
(3.3 Mb)
PDF